marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
CytomX Therapeutics Balance Sheet 2011-2024 | CTMX
Annual Balance Sheet CytomX Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.2 M | -176 M | -184 M | -167 M | - | -248 M | -178 M | -105 M | -59.8 M | -61.4 M | -4.5 M | - | - |
Long Term Debt |
9.38 M | 14 M | 18.1 M | 21.7 M | - | - | - | - | - | 1.57 M | 2.94 M | - | - |
Long Term Debt Current |
4.59 M | 4.08 M | 3.62 M | 3.2 M | 2.81 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 228 M | 267 M | 84.9 M | 55.4 M | 140 M | 54.3 M | - | - |
Total Current Liabilities |
156 M | 153 M | 77.9 M | 68.1 M | 85.6 M | 97.9 M | 61.1 M | 35.8 M | 15.7 M | - | - | - | - |
Total Liabilities |
249 M | 347 M | 340 M | 366 M | 290 M | 326 M | 328 M | 121 M | 71.1 M | 152 M | 58.5 M | - | - |
Deferred Revenue |
132 M | 121 M | 40.8 M | 42.1 M | 51.4 M | 52.7 M | 40.6 M | 20.3 M | 6.13 M | 6.13 M | 857 K | - | - |
Retained Earnings |
-723 M | -723 M | -624 M | -508 M | -443 M | -315 M | -219 M | -176 M | -117 M | -78.1 M | -43.9 M | - | - |
Total Assets |
202 M | 261 M | 339 M | 359 M | 341 M | 457 M | 398 M | 199 M | 197 M | 73.1 M | 14.2 M | - | - |
Cash and Cash Equivalents |
17.2 M | 194 M | 206 M | 192 M | 188 M | 248 M | 178 M | 105 M | 59.8 M | 64.4 M | 8.7 M | - | - |
Book Value |
-47.4 M | -85.8 M | -459 K | -7.77 M | 51.1 M | 131 M | 69.9 M | 78.5 M | 126 M | -78.5 M | -44.3 M | - | - |
Total Shareholders Equity |
-47.4 M | -85.8 M | -459 K | -7.77 M | 25.5 M | 131 M | 69.9 M | 78.5 M | 126 M | -78.5 M | -44.3 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet CytomX Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5.6 M | 6.88 M | 8.15 M | 10.6 M | 11.7 M | 12.9 M | 14 M | 15.1 M | - | 17.1 M | 18.1 M | 19 M | 19.9 M | 20.8 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.57 M | 1.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
162 M | 190 M | 216 M | 272 M | 294 M | 321 M | 347 M | 198 M | - | 229 M | 250 M | 260 M | 271 M | 288 M | 309 M | 309 M | 309 M | 309 M | 290 M | 290 M | 290 M | 290 M | 326 M | 326 M | 326 M | 326 M | 328 M | 328 M | 328 M | 328 M | 121 M | 121 M | 121 M | 121 M | 71.1 M | 71.1 M | 71.1 M | 71.1 M | 74.9 M | 74.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
96.1 M | 124 M | 124 M | 124 M | 120 M | 127 M | 121 M | 61.3 M | - | 70 M | 69.3 M | 73.1 M | 72.4 M | 76.6 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 52.7 M | 52.7 M | 51.5 M | 47 M | 40.6 M | 56.9 M | 46.8 M | 40.6 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 6.13 M | 6.13 M | 6.13 M | 6.13 M | 6.13 M | 6.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-710 M | -716 M | -710 M | -724 M | -727 M | -726 M | -723 M | -605 M | - | -558 M | -534 M | -507 M | -485 M | -466 M | -450 M | -450 M | -450 M | -450 M | -417 M | -417 M | -417 M | -417 M | -315 M | -315 M | -315 M | -315 M | -219 M | -219 M | -219 M | -219 M | -176 M | -176 M | -176 M | -176 M | -117 M | -117 M | -117 M | -117 M | -78.1 M | -78.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
139 M | 159 M | 185 M | 221 M | 209 M | 235 M | 261 M | 226 M | - | 297 M | 339 M | 371 M | 402 M | 434 M | 359 M | 359 M | 359 M | 359 M | 341 M | 341 M | 341 M | 341 M | 457 M | 457 M | 457 M | 457 M | 398 M | 398 M | 398 M | 398 M | 199 M | 199 M | 199 M | 199 M | 197 M | 197 M | 197 M | 197 M | 73.1 M | 73.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
40.6 M | 43.2 M | 36.2 M | 26 M | 57.5 M | 56.4 M | 194 M | 95 M | 129 M | 163 M | 206 M | 236 M | 256 M | 330 M | 192 M | 192 M | 192 M | 192 M | 188 M | 188 M | 188 M | 188 M | 248 M | 248 M | 248 M | 248 M | 178 M | 178 M | 178 M | 178 M | 105 M | 105 M | 105 M | 105 M | 59.8 M | 59.8 M | 59.8 M | 59.8 M | 64.4 M | 64.4 M | - | - | 8.7 M | - | - | - | 14.7 M | - | - | - | - | - | - | - |
Book Value |
-23.5 M | -31.2 M | -31.7 M | -51.2 M | -85 M | -86.6 M | -85.8 M | 28.5 M | - | 68.2 M | 89.4 M | 112 M | 131 M | 146 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 51.1 M | 51.1 M | 51.1 M | 51.1 M | 131 M | 131 M | 131 M | 131 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 78.5 M | 78.5 M | 78.5 M | 78.5 M | 126 M | 126 M | 126 M | 126 M | -1.83 M | -1.83 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-23.5 M | -31.2 M | -31.7 M | -51.2 M | -85 M | -86.6 M | -85.8 M | -80.5 M | -54.5 M | -29.7 M | 89.4 M | 112 M | 131 M | 146 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 51.1 M | 51.1 M | 51.1 M | 51.1 M | 131 M | 131 M | 131 M | 131 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 78.5 M | 78.5 M | 78.5 M | 78.5 M | 126 M | 126 M | 126 M | 126 M | -78.5 M | -78.5 M | - | - | -44.3 M | - | - | - | -26 M | - | - | - | - | - | - | - |
All numbers in USD currency